ScholarIQanswers from OpenAlex & ORCID
Ihor Vynnychenko
ResearcherPublications, citations & collaboration network
Ihor Vynnychenko is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ihor Vynnychenko have?
ScholarIQindexed works
Ihor Vynnychenko has 99 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ihor Vynnychenko have?
ScholarIQcitation count
Ihor Vynnychenko has 21,265 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ihor Vynnychenko?
ScholarIQh-index
Ihor Vynnychenko has an h-index of 33 in OpenAlex.
What is the i10-index of Ihor Vynnychenko?
ScholarIQi10-index
Ihor Vynnychenko has an i10-index of 47 in OpenAlex.
What is the ORCID of Ihor Vynnychenko?
ScholarIQorcid
The ORCID for Ihor Vynnychenko is on the source record.
What is the OpenAlex record for Ihor Vynnychenko?
ScholarIQopenalex
The OpenAlex for Ihor Vynnychenko is on the source record.
What are the most-cited papers on Ihor Vynnychenko?
ScholarIQmost cited works
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, А. Л. Акопов, Alex Martínez‐Martí, Hirotsugu Kenmotsu, Yuh‐Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark L. McCleland, Elizabeth Bennett, Barbara J. Gitlitz, Heather A. Wakelee
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth J. O’Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, U. Gatzemeier
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski